Background. Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) infection during pregnancy was associated with a number of adverse pregnancy outcomes, including miscarriage, preeclampsia, preterm birth, and stillbirth. The virus persistence can last for a long time, and the consequences of a previous coronavirus infection are currently under study. Objectives. This study aimed to establish the clinical features of the course of pregnancy and childbirth in women with a history of asymptomatic coronavirus disease 2019 (COVID-19). Methods. This study was conducted in the Regional Perinatal Center N3 of Turkestan city, Kazakhstan. A total of 229 participants were enrolled comprising individuals with (n = 133, exposed group) from August to September 2021 with a history of COVID-19 and without one in the same period in 2019 (n = 96, unexposed group). Results. There is a statistically significant strong association between a history of COVID-19 and the development of oligohydramnios (φ = 0.743, p < 0.001), and medium strength between a history of COVID-19 and the presence of anemia (φ = 0.254, p < 0.001), abnormal development of the placenta (φ = 0.254, p < 0.011), cord entanglement (φ = 0.343, p = 0.000), low birth weight (φ = 0.356, p < 0.001) and stillbirth (φ = 0.293, p < 0.001). Conclusions. The past COVID-19 infection in pregnant women has long-term consequences in the form of placenta abnormal development and oligohydramnios; and, as a result, the development of adverse perinatal outcomes

Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) infection during pregnancy was associated with a number of adverse pregnancy outcomes, including miscarriage, preeclampsia, preterm birth, and stillbirth. The virus persistence can last for a long time, and the consequences of a previous coronavirus infection are currently under study. This study aimed to establish the clinical features of the course of pregnancy and childbirth in women with a history of asymptomatic coronavirus disease 2019 (COVID-19). This study was conducted in the Regional Perinatal Center N3 of Turkestan city, Kazakhstan from August to September 2021. A total of 229 participants were enrolled comprising individuals with (n=133, exposed group) or without a history of COVID-19 (n=96, unexposed group). There is a statistically significant strong relationship between a history of COVID-19 and the development of oligohydramnios (φ=0.743, p<0.001); medium strength between a history of COVID-19 and the presence of anemia, abnormal development of the placenta, cord entanglement, low birth weight and stillbirth (p<0.001). The past COVID-19 infection in pregnant women have long-term consequences in the form of placenta abnormal development and oligohydramnios, and as a result, the development of adverse perinatal outcomes.

Background/Objectives: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease characterized by irreversible airway obstruction. This study aims to investigate the associations between COPD and its phenotypes with polymorphic variants of the IREB2 and CHRNA5 genes in the Kazakhstan population. Methods: A case–control study was conducted involving 265 COPD patients and 267 controls. Genotyping of the IREB2 polymorphisms rs13180 and rs2568494, as well as CHRNA5 rs16969968 polymorphism, was performed using real-time polymerase chain reactions (Real-Time PCRs). Results: A higher frequency of the AA genotype of the IREB2 rs2568494 polymorphism was identified in COPD patients with moderate to very severe airflow obstruction (Chronic Obstructive Lung Disease (GOLD) stages II, III, and IV), with an odds ratio of 0.69 (95% CI = 0.23–2.10; Padj = 0.03). The IREB2 rs13180 polymorphism was significantly more frequent or prevalent in smokers and showed a correlation with FEV₁ (forced expiratory volume in one second) (β = 7.79, SE = 2.98, p = 0.01) and FEV₁/ FVC (forced vital capacity) (β = 9.51, SE = 2.95, p = 0.002). Additionally, the CC genotype of this polymorphism was associated with clinical manifestations of COVID-19 in COPD patients (χ²= 3,95, df = 2, p = 0.05). Conclusions: Our study identified a significant association between the IREB2 rs2568494 polymorphism and an increased risk of severe COPD. The IREB2 rs13180 polymorphism was linked to smoking behavior, as well as key lung function indicators, suggesting its potential role in disease progression and lung damage. Furthermore, the CC genotype of the IREB2 rs13180 polymorphism was associated with clinical manifestations of COVID-19 in COPD patients, indicating a potential impact of this genetic variant on susceptibility to viral infections in this population.